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Catestatin (Cst) is a 21-amino acid peptide deriving from Chromogranin A. Cst exerts an
overall protective effect against an excessive sympathetic stimulation of cardiovascular sys-
tem, being able to antagonize catecholamine secretion and to reduce their positive inotropic
effect, by stimulating the release of nitric oxide (NO) from endothelial cells. Moreover, Cst
reduces ischemia/reperfusion (I/R) injury, improving post-ischemic cardiac function and car-
diomyocyte survival. To define the cardioprotective signaling pathways activated by Cst
(5 nM) we used isolated adult rat cardiomyocytes undergoing simulated I/R. We evaluated
cell viability rate with propidium iodide labeling and mitochondrial membrane potential
(MMP) with the fluorescent probe JC-1. The involvement of Akt, GSK3β, eNOS and phos-
pholamban (PLN) cascade was studied by immunofluorescence. The role of PI3K-Akt/NO/
cGMP pathway was also investigated by using the pharmacological blockers wortmannin
(Wm), L-NMMA and ODQ. Our experiments revealed that Cst increased cell viability rate by
65% and reduced cell contracture in I/R cardiomyocytes. Wm, L-NMMA and ODQ limited
the protective effect of Cst. The protective outcome of Cst was related to its ability to main-
tain MMP and to increase AktSer473, GSK3βSer9, PLNThr17 and eNOSSer1179 phosphoryla-
tion, while treatment with Wm abolished these effects. Thus, the present results show that
Cst is able to exert a direct action on cardiomyocytes and give new insights into the molecu-
lar mechanisms involved in its protective effect, highlighting the PI3K/NO/cGMP pathway
as the trigger and the MMP preservation as the end point of its action.
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Introduction
In the last decade, several biologically active peptides derived from Chromogranin A (CgA), in-
cluding Vasostatin-1 (VS-1) and Catestatin (Cst), have received attention as regulators of car-
diovascular function [1–4]. CgA is highly conserved in the vertebrate secretory granules of
both the diffuse neuroendocrine system and the heart itself, in which it colocalyzes with cate-
cholamines and atrial and brain natriuretic peptides [5]. Initially used as a marker of several
diseases such as neuro-endocrine tumors or neuro-degenerative dysfunctions [6], CgA recently
emerged as a biomarker of cardiovascular pathologies such as essential hypertension [1–4],
heart failure [7] and hypertrophic or dilatative cardiomyopathy [5]. The involvement of CgA
in cardiovascular homeostasis is supported by its function as a pro-hormone. Among the prod-
ucts of CgA identified, Cst, initially described as a peptide exhibiting a catecholamine release-
inhibitory action [1–4], displays several in vivo and in vitro effects on the heart and vasculature
[8–11]. Cst exerts a vasodilator effect [8] and participates to blood pressure regulation: low Cst
plasma levels have been measured not only in patients affected by essential hypertension, but
also in their still normotensive offspring [12, 13]. Consistent with human findings [8, 12, 13],
the severe hypertension, the dampened baroreflex sensitivity and the heart rate variability de-
veloped in knock-out mice for the CHGA gene can be rescued by the replacement with this
peptide [14, 15]. Cardiac secretory granules containing CgA, CgB and Secretogranin 2 are pres-
ent in murine heart. In particular, the fact that CgA is processed to Cst strongly suggests an au-
tocrine/paracrine function of Cst within cardiac tissue [16]. Cst exerts a negative inotropic
effect on the isolated rat heart and papillary muscle, both under basal conditions and in pres-
ence of β-adrenergic stimulation [9–10]. These effects were not due to a direct action on cardi-
omyocytes, but rather related to the activation of PI3K-Akt-eNOS pathway and NO release
from endothelial cells [10]. At present, among the different actions of Cst on the heart, some
need to be fully elucidated. The finding that Cst exerts a protective effect against I/R injury in
isolated rat hearts [17, 18] has been questioned by other Authors, showing that Cst may also
exert deleterious effects in these conditions [19]. In addition, our knowledge on the signaling
pathways involved in the cardiovascular responses to CgA-derived peptides is, at present, only
fragmentary. As typical high-affinity receptors have not been identified, the cellular processes
upstream eNOS activation exerted by these peptides are still partially unknown [1–4]. In a
recent work investigating the mechanism responsible for VS-1-mediated eNOS activation in
endothelial cells, we showed that it involves a proteoglycans-phosphatidylinositol-4,5-bipho-
sphate 3-kinase (PI3K)-dependent caveolae endocytosis as the initiating factor, providing an
appealing novel signaling pathway expected for receptor-orphan peptides with membrane-in-
teracting properties [20].
Although a number of experiments strongly suggests that endothelial cells play a fundamen-
tal role in mediating the effects of CgA-derived peptides on myocardium [10, 21], recent obser-
vations from our laboratory indicate that Cst is able to exert cardioprotective effects also via a
direct effect, independent from endothelial cells, on isolated cardiomyocytes undergoing I/R
[17]. Interestingly, this effect was attained at a very low concentration, comparable to the circu-
lating concentrations of Cst in healthy humans [22]. These results reopen the question con-
cerning the presence of specific receptors for Cst on cardiac cells, suggesting that the effects of
CgA-derived peptides are, at least in part, independent from endothelial cells.
Therefore, besides to further confirm the direct cardioprotective effect exerted by Cst on iso-
lated adult rat cardiomyocytes, the aim of the present study was to clarify the mechanisms and
the signaling pathways involved in the action of this peptide. To this purpose, we evaluated the
effects of Cst on cell viability and mitochondrial membrane potential stabilization on adult rat
cardiomyocytes undergoing simulated I/R. The involvement of protein kinase B (AktSer473),
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glycogen synthase kinase 3β (GSK3βSer9), endothelial nitric oxide synthase (eNOSSer1179) and
phospholamban (PLNThr17) cascade was studied by immunofluorescence in the presence of the
PI3K inhibitor wortmannin (Wm).
Materials and Methods
Animals
Experiments were performed on young adult CD1IGS rats (body weight 200–300 g), which
were allowed ad libitum access to tap water and standard rodent diet. The animals received
human care in compliance with the Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996), and
in accordance with Italian law (DL-116, Jan. 27, 1992). The scientific project was supervised
and approved by the Italian Ministry of Health, Rome, and by the Committee on the Ethics of
Animal Experiments of the University of Torino (session of 7/07/2010). Rats were anaesthe-
tized by i.p. injection of Pentobarbital (Nembutal, 100 mg/Kg) and killed by stunning and
cervical dislocation.
Solutions and drugs
Tyrode standard solution contained (mM): 154 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 5.5 D-glucose,
5 HEPES, pH adjusted to 7.4 with NaOH. Ca2+ free Tyrode solution contained (mM): 135
NaCl, 4 KCl, 1 MgCl2, 2 HEPES, 10 glucose, 10 butanedione monoxime, 5 taurine; pH adjusted
to 7.4 with NaOH. Ischemic buffer (IB) solution contained (mM): 137 NaCl, 3.5 KCl, 0.88
CaCl2, 0.51 MgSO4, 5.5 D-Glucose, 4 HEPES, 10.2 deoxy-D-Glucose, 20 DL-lactic acid; pH ad-
justed to 6.5 with NaOH. Phosphate Buffer saline (PBS) solution contained (mM): 137 NaCl,
2.7 KCl, 10 Na2HPO4 • 2 H2O, 1.76 KH2PO4; pH adjusted to 7.4 with NaOH. All drug-contain-
ing solutions were prepared fresh before the experiments; except IB, all solutions were oxygen-
ated (O2 100%) before each experiment.
Ventricular cells isolation
After sacrifice, the hearts were explanted, washed in modified Ca2+ free Tyrode solution and
cannulated via the aorta. Hearts were perfused at a constant flow rate of 10 ml/min with Ca2+
free Tyrode solution with a peristaltic pump for approximately 5 min (37°C) to wash away the
blood, then with 10 ml of Ca2+ free Tyrode supplemented with collagenase (0.3 mg/ml) and
protease (0.02 mg/ml) and, finally, perfused and enzymatically dissociated with 30 ml of Ca2+
free Tyrode containing 50 μMCaCl2 and the same enzymatic concentration mentioned before.
Ventricles were then separated from the atria, cut in small pieces and shaken for 10 minutes in
20 ml of Ca2+ free Tyrode solution in presence of 50 μMCaCl2, collagenase and protease.
Experimental design
The experimental protocol for simulated I/R experiments is shown in Fig. 1. Control group
(CTRL) cardiomyocytes were superfused with Tyrode standard solution for 25 min. In ische-
mic/reperfused (I/R) group, cardiomyocytes were superfused with Tyrode standard solution
for 5 min, followed by IB perfusion for 15 min, and reperfused with Tyrode standard solution
for 5 min. In Ischemic + Cst group (Cst), cardiomyocytes were treated with 5 nM Cst during
the first 5 min of superfusion with Tyrode standard and along the entire IB treatment; reperfu-
sion occurred in the presence of Tyrode standard solution alone. Wortmannin (Cst + Wm), L-
NMMA (Cst + L-NMMA) and ODQ (Cst + ODQ) groups: cardiomyocytes were treated as Cst
Intracellular Pathways Mediating Catestatin Induced Cardioprotection
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Fig 1. Experimental design.Control group (CTRL) cardiomyocytes were superfused/reperfused with Tyrode standard solution for 25 min. Ischemic/
reperfused group (I/R): superfusion with Tyrode standard for 5 min, ischemic buffer (IB) for 15 min, and Tyrode standard (reperfusion) for 5 min. Ischemic +
Cst group (Cst): superfusion with Tyrode standard + 5 nM Cst for 5 min, IB + 5 nM Cst for 15 min, and Tyrode standard alone for 5 min (reperfusion).
Wortmannin (Cst + Wm), L-NMMA (Cst + L-NMMA) and ODQ (Cst + ODQ) groups: cardiomyocytes were treated as Cst group, in the presence of 100 nM
Wm, 1 mM L-NMMA or 100 μMODQ together with 5 nM Cst.
doi:10.1371/journal.pone.0119790.g001
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group, in the presence of 100 nMWm, 1 mMNG-monomethyl-L-arginine (L-NMMA) or
100 μM 1H-[1,2,4]oxidiazolo[4,3-a]quinoxaline-1-one(ODQ) together with 5 nM Cst.
Cell viability
Cell viability was evaluated by propidium iodide (PI, 10 μg/ml, Invitrogen) labeling. Images
were acquired using a laser scanning confocal system (Fluoview 200, Olympus America, Mel-
ville, NY) with an Ar/Kr laser (488 and 568 nm) mounted on an inverted microscope (model
IX70, Olympus) equipped with a ×20 UplanApo (NA 0.90). Confocal image acquisitions for
each experimental condition were performed at the times t5, t20, and t25, as indicated in Fig. 1.
Immunofluorescence and confocal microscopy
Cardiomyocytes were fixed for 30 minutes in 4% paraformaldehyde in 0.1 M phosphate buffer
(PB), pH 7.3. After three washes with PBS, cells were incubated 20 minutes with 0.3% Triton
and 1% bovine serum albumin (BSA, Sigma) in PBS and stained with the primary antibody
24 h at 4°C. Cover slides were washed twice with PBS and incubated 1h at room temperature
with the secondary antibody. After two washes in PBS cover slides were mounted on standard
slides with DABCO (Sigma) and observed after 24h under confocal microscope. We used a
monoclonal anti-eNOS antibody (BD Biosciences, 1:50), a polyclonal anti-eNOSSer1179 anti-
body (Invitrogen, 1:10), a polyclonal anti-GSK3β Ser9 (Cell signaling 1:200), a polyclonal anti-
AktSer473 antibody (Cell signaling 1:200), a polyclonal anti-PLN antibody (Cell signaling
1:500), PLNThr17 (Cell signaling 1:200). Secondary antibodies employed for immunofluores-
cence experiments were Alexa Fluor 488 anti-mouse (Molecular Probes) for total eNOS and
Cy3 anti-rabbit (Sigma) for P-eNOSSer1179, P-PLNThr17 and P-GSK3β Ser9.
Confocal fluorimetric measurements were performed using an Olympus Fluoview 200 laser
scanning confocal system (Olympus America Inc., Melville, NY, USA) mounted on an inverted
IX70 Olympus microscope, equipped with a 60X Uplan FI (NA 1.25) oil-immersion objectives.
Image processing and analysis were performed with ImageJ software (Rasband, W.S., U. S. Na-
tional Institutes of Health, Bethesda, MA, http://rsb.info.nih.gov/ij/, 1997–2012).
Mitochondrial membrane potential measurement
MMP was measured with a unique cationic dye of 5,5',6,6'-tetrachloro 1,1',3,3'-tetraethylbenzi-
midazolcarbocyaenina iodide (JC-1). Briefly, cells were stained with JC-1 (5 μg/ml) at 37°C for
30 min and then washed once with Tyrode standard solution. Then cells were treated accord-
ing to the experimental protocol described above (Fig. 1). In living cells mitochondria appear
red, due the aggregation of accumulated JC-1 (absorption/emission maxima of 585/590 nm),
while the dye remains green in its monomeric form (absorption/emission maxima of 510/
530 nm). In dead (apoptotic or necrotic) cells the dye is present almost only in the monomeric
form (green fluorescence). For each cell the average intensity of green and red fluorescence was
determined, and the ratio of JC-1 monomer (green) to aggregate (red) was calculated. An in-
crease in this ratio was thus interpreted as an increase in mitochondrial membrane potential
[23]. Image processing and analysis were performed with ImageJ software.
Statistical analysis
Values are shown as means ± S.E.M. Statistical analysis was performed with either ANOVA
followed by the Newman-Keuls multi-comparison test or the Student t test when appropriate.
A p value< 0.05 was considered significant.
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Results
Cst preserves cell viability and reduces contracture in I/R
cardiomyocytes
Simulated I/R protocol markedly reduced the number of surviving cells respect to control
(CTRL) group (18.1 ± 11.09% and 95.5 ± 3.1%, respectively). Cst 5 nM significantly preserved
cell viability during reperfusion (63.45 ± 17.1%; p< 0.05; 5 experiments, at least n = 45 cells
for each condition). The protective effect of Cst was completely blocked when cardiomyocytes
were pre-treated with Wm 100 nM (21.0 ± 8.6%). The cardioprotective effect of Cst against I/R
damage was further evaluated in terms of cardiomyocytes contracture. For each experimental
condition, cell length was measured at t5 and t25 (the last corresponding to the end of the re-
perfusion phase). No significant variation of cell length was observed in CTRL group (from
111.8 ± 8.7 to 107.22 ± 9 μm, n = 18 cells). The marked reduction occurring during the reperfu-
sion phase in the I/R group (from 95.0 ± 4.3 to 55.4 ± 3.7 μm; p< 0.001; n = 22 cells) was sig-
nificantly reduced in Cst group (from 109.3 ± 3.2 to 104.6 ± 5.1 μm, n = 16 cells). In order to
characterize the mechanism of action and the signaling pathways involved in the cardio-pro-
tection exerted by Cst, we performed additional experiments in the presence of pharmacologi-
cal blockers of PI3K-Akt, NO and cGMP synthesis (Wm, L-NMMA and ODQ, respectively).
All these drugs reduced the protective effect of Cst, and a remarkable contracture was observed
again in cells of Cst + Wm (from 109.6 ± 6.9 to 79.7 ± 8.9 μm; n = 11 cells p< 0.01 respect to
Cst group), Cst + L-NMMA (from 110.5 ± 8.4 to 95.6 ± 8.6 μm; n = 12 cells; p< 0.05 respect to
Cst group) and Cst + ODQ (from 110.8 ± 4.7 to 91.5 ± 3.9 μm; n = 20 cells; p< 0.05 respect to
Cst group) groups.
The cardioprotective effect of Cst involves Akt, GSK3β and eNOS
activation
To further investigate the role of PI3K-Akt/NO/cGMP pathway in the cardio-protection ex-
erted by Cst, we performed immunofluorescence experiments on fixed cells exposed to simu-
lated I/R, according to the protocol described in Fig. 1. Besides to verify whether Cst was able
to modulate the phosphorylation of Akt and eNOS, we tested also the effect of Cst on GSK3β,
another key enzyme involved in cardioprotection, included with Akt and eNOS in the reperfu-
sion injury salvage kinase (RISK) pathway [24–27]. As indicated in Fig. 2 (A, B), I/R protocol
caused a dramatic fall in the phosphorylation of AktSer473; Cst preserved the phosphorylation
of this kinase, the level of which was comparable to that measured in control cells. The protec-
tive effect of Cst was abrogated in cells pretreated with Wm. Similar results were obtained for
GSK3βSer9: after I/R, Cst significantly increased the phosphorylation of GSK3βSer9 in compari-
son to the I/R group (Fig. 2 C, D); also in this case, phosphorylation level was significantly re-
duced in the presence of Cst + Wm (p< 0.05). As shown in Fig. 3 (A, B), in cardiomyocytes
undergoing I/R, Cst was also able to maintain phosphorylation of eNOSSer1179 at a level compa-
rable to that observed in CTRL cells, whereas in Cst + Wm samples this value was similar to
that recorded in I/R group (p< 0.05).
Cst maintains PLN activation
In order to study whether Cst is able to favour Ca2+ uptake by the sarcoplasmic reticulum
under I/R conditions, we performed immunofluorescence experiments to test PLNThr17 phos-
phorylation. We observed that, while in untreated ventricular cells PLNThr17 phosphorylation
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level fell during reperfusion, Cst was able to maintain significantly higher levels of P-PLN
during reperfusion (Fig. 3 C, D). The effect of Cst was completely abrogated by the treatment
with Wm.
Fig 2. Cst preserves Akt and GSK3β activation during reperfusion. A) Fluorescence confocal images of cardiomyocytes labeled with anti phospho-
Akt473 antibody in CTRL, I/R, Cst and Cst+Wm groups. B) Statistical analysis of the simulated I/R experiments. C) Fluorescence confocal images of
cardiomyocytes labeled with anti phospho-GSK3βSer9 antibody in CTRL, I/R, Cst and Cst+Wm groups. D) Statistical analysis of the simulated I/R
experiments. For both Akt and GSK3β, fluorescence intensity (mean ± S.E.M. from at least 25 cells; n = 5 experiments) was expressed in arbitrary units
(A.U.) for each treatment at the end of reperfusion phase. Statistical comparison was performed by one-way ANOVA followed by NM test for post hoc
analysis (in this and the following figures: *p< 0.05; **p<0.01).
doi:10.1371/journal.pone.0119790.g002
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Cst preserves mitochondrial membrane potential in I/R cardiomyocytes
To further investigate the potential protective effect of Cst against cell death induced by I/R, we
finally evaluated its ability to maintain mitochondrial membrane potential in these conditions.
To this purpose, we used the specific lipophilic cationic dye JC1, that exhibits a potential-de-
pendent accumulation into the mitochondria displayed as a fluorescence emission shift from
green (cytosolic) to red (mitochondrial) [23]. As indicated in Fig. 4, while in CTRL condition
the green/red ratio of fluorescence variation was maintained constant throughout the entire
time course of the experiment, in the I/R group the ratio began to increase at the end of the
Fig 3. Cst maintains eNOS and PLN activation during reperfusion. A) Fluorescence confocal images of cardiomyocytes labeled with anti phospho-
eNOS1179 antibody in CTRL, I/R, Cst and Cst+Wm groups. B) Statistical analysis of the simulated I/R experiments. C) Fluorescence confocal images of
cardiomyocytes labeled with anti phospho-PLNThr 17 (green fluorescence) antibody and with anti PLN antibody (red fluorescence) in CTRL, I/R, Cst and
Cst+Wm groups. D) Statistical analysis of the simulated I/R experiments. For both eNOS and PLN, fluorescence intensity (mean ± S.E.M. from at least 25
cells; n = 5 experiments) was expressed as percentage respect I/R group for each treatment at the end of reperfusion phase.
doi:10.1371/journal.pone.0119790.g003
Intracellular Pathways Mediating Catestatin Induced Cardioprotection
PLOS ONE | DOI:10.1371/journal.pone.0119790 March 16, 2015 8 / 13
ischemic phase (t20), and further enhanced during reperfusion (t25). In cells treated with Cst
the ratio of fluorescence variation was maintained constant for the entire experimental time
course, in a fashion comparable to that of the CTRL group. Finally, the treatment of cells with
Wm increased the green/red ratio to values comparable to those recorded in the case of the I/R
group. As indicated in the bar graph (Fig. 4 B), Cst significantly reduced the green/red ratio of
Fig 4. Cst preservesmitochondrial membrane potential in cardiomyocytes undergoing I/R. A) Fluorescence confocal images of cardiomyocytes
labeled with JC-1 fluorescent probe at t5, t20 and t25 min of each experiment. B) Statistical analysis of green/red ratio (green: monomeric form; red:
aggregate) of fluorescence variation. These values were referred to the end of the reperfusion phase. Results are presented as mean ± S.E.M. from at least
25 cells; n = 5 experiments.
doi:10.1371/journal.pone.0119790.g004
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fluorescence respect to the I/R group, being able to rescue the physiological mitochondrial
membrane potential values in myocardial cells undergoing I/R.
Discussion
This study focused on the mechanisms responsible for the protective effect of Cst in isolated
cardiomyoctes exposed to simulated I/R. Our findings indicate that Cst could limit I/R injury
by stimulating key enzymes included in the RISK pathway, such as Akt, GSK3β and eNOS, and
maintaining high PLNThr17 phosphorylation levels, converging on MMP preservation. More-
over, the protection observed is primarily due to a direct effect on cardiomyocytes and does not
necessarily depend on the endothelial effects of Cst. Interestingly, Cst-dependent cardioprotec-
tion was attained at a very low concentration, comparable to the circulating levels of this pep-
tide found in healthy humans [22].
The cardioprotective effect of Cst involves Akt, GSK3β and eNOS
activation
Previous studies indicated that the inotropic effects of Cst are mediated by PI3K/Akt/eNOS/
cGMP pathway [9–11]. Besides playing a key role in mediating intracardiac signaling involved
in the control of contractile performance, this system is also involved in cardioprotection of I/R
heart. In fact, among the signaling pathways underlying preconditioning, great attention has
focused on the cGMP/protein kinase G (PKG) and on the RISK pathways, the last involving
both Akt and the extracellular signal regulated kinase (ERK1/2). All these intracellular signal-
ing cascades converge on the mitochondria via the modulation of several kinases, including
GSK3β, Bax/Bad and the ε isoform of protein kinase C (PKC- ε) [24–27].
We thus hypothesized that the activation of these pathways are also responsible for the car-
dio-protective effect afforded by Cst. In line with this hypothesis, we show here that Cst is able
to maintain high Akt, GSK3β and eNOS phosphorylation levels in isolated cardiomyocytes un-
dergoing I/R. The blocking effect of Wm, L-NMMA and ODQ further confirms that the pro-
tective effect of Cst is due to the activation PI3K and eNOS, leading to cGMP synthesis.
In particular, the present study further proves the role of Akt in the cardioprotective effect
of Cst against I/R-induced damage in the isolated rat heart [17, 18]. In contrast with these re-
sults, it has been reported that under certain conditions Cst does not activate Akt and exerts
deleterious effects [19]. These conflicting results may be due to the different models of ischemia
(e.g., global vs. regional ischemia) and/or the dose/duration of treatment used. Several agents,
indeed, may be protective or deleterious when certain conditions have changed [27]. Interest-
ingly, similarly to cardiomyocytes, anti-apoptotic Akt-dependent properties on endothelial
cells have been recently described for Cst [28].
The ability of Cst to induce eNOS phosphorylation at the beginning of reperfusion is in
agreement with studies performed on the isolated rat heart, in which both NO concentration
and eNOS activity are increased during the first minutes of reperfusion [29]. The present study
further confirms that GSK3β plays an important role in protection of cardiomyocytes exposed
to I/R damage. Several recent studies support the notion that mitochondrial GSK3β plays a pre-
dominant role in myocyte necrosis after I/R injury. For instance, the threshold for mitochon-
drial permeability transition pores (mPTP) opening in response to reacting oxygen species
(ROS) was significantly attenuated by both GSK3β inactivation or expression knockdown in
cardiomyocytes [30]. The prevention of mPTP opening induced by Cst in the isolated I/R rat
heart [17, 18] may thus be related to the ability to maintain the high GSK3β phosphorylation
levels observed in our present experiments.
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Cst maintains PLN activation
By opening of mPTP, intracellular calcium overload occurring during reperfusion has a crucial
role in mitochondrial dysfunction, hypercontracture and cell death [31]. We recently reported
that in isolated rat I/R hearts, the administration of Cst during early reperfusion limited dia-
stolic contracture and improved post-ischemic systolic function [17, 18]. Limited contracture
is likely due to a reduced calcium overload resulting either from calcium extrusion and/or from
increased re-uptake by sarco/endoplasmic reticulum Ca2+-ATPase (SERCA). While the former
may reduce contractility, the latter tends to increase it. It has been suggested that RISK pathway
activation may stimulate SERCA, thus enhancing calcium uptake into the sarcoplasmic reticu-
lum, reducing calcium overload and preventing mPTP opening and cell death [27, 32].
We observed that Cst is able to maintain high PLNThr17 phosphorylation levels in isolated
cardiomyocytes undergoing I/R, comparable to those recorded in the pre-ischemic period. In
cardiac cells, SERCA2a activity is modulated by PLN, the activity of which may be in turn regu-
lated by phosphorylation in both Ser16 and/or Thr17 residues. While PLNSer16 phosphoryla-
tion mainly accounts for the inotropic and lusitropic effects of β-adrenergic stimulation,
PLNThr17 phosphorylation is related to cardioprotection [33]. In particular, it has been pointed
out that the phosphorylation of this residue is reduced after a prolonged period of ischemia
(30 min), but it is maintained by brief periods of intermittent hypoxia, thus inducing cardio-
protection [34]. In addition, it has been recently shown that activated Akt interacts and phos-
phorylates PLN at Thr17, thus improving Ca2+ handling and enhancing contractility [35].
Cst preserves mitochondrial membrane potential in I/R cardiomyocytes
Mitochondrial damage is a determining factor in causing loss of cardiomyocyte function and
viability during reperfusion injury. Major mechanisms of mitochondrial dysfunction include
the long lasting opening of mPTPs and the consequent collapse of MMP [32]. Cardioprotective
signaling pathways activated by both brief intermittent ischemic periods, such as precondition-
ing and postconditioning, and pharmacological agents converge on mitochondria to preserve
their function after I/R. Our present observation that Cst was able to preserve MMP in cardio-
myocytes undergoing I/R is in agreement with the previously reported ability of this peptide to
reduce cell death and to avoid MMP dissipation due to oxidative stress in cultured H9c2 cells
[18]. It is therefore reasonable that, as in the case of other cardioprotective agents, mitochon-
dria represent the shared end point target of the Cst-activated signaling pathways, and preser-
vation of their function thus corresponds to cell viability maintenance after I/R.
In conclusion, in the present work we demonstrated that Cst applied before and during an
ischemic period exerts a protective action against I/R damage in isolated adult rat cardiomyo-
cytes, by activating PI3K-Akt-GSK3β and eNOS pathways. Regarding in particular the role of
NO in catestatin-dependent cardioprotection, we have to take into account that a limitation of
the present model is the inability to evaluate the real contribution of autocrine NO production
in the intact heart, in which the endothelial generation of NO is overwhelming.
Our study confirms the relevant role of Cst as a modulator of cardiovascular system, both
under physiological and pathophysiological conditions. Thus, Cst may be considered a multi-
functional peptide able to act at different levels, from the baroceptor and sympatho-cromaffin
systems to the direct interaction with cardiomyocytes. In particular, our study highlights the
importance of PI3K-Akt-GSK3β and eNOS pathways in the cardioprotective role of Cst, un-
derlining its function in the stabilization of MMP and in the modulation of calcium signaling
within cardiac cells undergoing ischemia and reperfusion.
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